Clinical News

Fourth report of the biological therapy element of the UK IBD audit

Thursday, 24 September 2015 14:32

Latest UK IBD audit report shows further improvement for patients following treatment with biological therapies

The UK inflammatory bowel disease (IBD) clinical audit report reveals today that the majority of patients (80% adult and 77% paediatric) with Crohn's disease saw an improvement following biological therapies

This is the fourth report of the biological therapy element of the UK IBD audit. The purpose of this audit is to measure the efficacy, safety and appropriate use of the biological therapies infliximab and adalimumab, also known as anti-TNFα drugs, in patients with IBD in the UK. The audit also aims to capture patients’ views on their quality of life at intervals during their treatment.

The data presented in the reports demonstrate that biological therapies for IBD are effective and relatively safe treatments. Patterns of use are changing, with earlier use in patients with less severe disease. It is likely that this reflects more appropriate prescribing as physicians become more familiar with these drugs.

National and executive summary versions of both adult and paediatric reports are available on the Royal College of Physicians' website:

NICE guidance on the use of vedolizumab in Crohn's disease

Wednesday, 26 August 2015 08:53

Single Technology Appraisal (STA) - Vedolizumab for the treatment of adult patients with moderately to severely active Crohn's disease [ID690]

The Final Guidance will be published on the NICE website: on 26th August 2015. There will also be a version of the guidance available for people using services, carers and the public called 'Information for the public'. Additionally, the documentation used to develop the guidance such as the underpinning evidence submissions, will remain on the website.

A copy of the guidance is available for you to download from NICE Docs:

"The BSG welcomes the publication of this guidance on the use of Vedolizumab in Crohn's disease. A significant number of patients suffering from Crohn's disease fail to benefit from anti-TNF therapy, and for them the availability of a drug therapy that has a completely different mode of action, with good trial evidence of efficacy and safety is most welcome."

Dr AB Hawthorne,
IBD section chairman

Applications for Future Hospital 2015 development sites open in September

Friday, 21 August 2015 13:24

The Future Hospital Programme (FHP) is looking for projects currently delivering integrated care for people across a health economy and aligned to the principles set out in the Future Hospital Commission report. The FHP is keen to work with project teams who are developing more efficient and cost-effective healthcare models for people with long-term conditions or complex health needs.

Applications open on 7 September 2015, and the submission deadline is 2 October 2015.

Click here for selection criteria details or This e-mail address is being protected from spambots. You need JavaScript enabled to view it . Click here for more information about current FHP development sites.

Through the 'Tell us your story' initiative, the FHP is showcasing examples of good practice to improve patient care, which will feature as case studies on the RCP website. To share your story with us download a form here.

New Global Enteral Device Connector

Wednesday, 12 August 2015 09:13

Dr Sheldon Cooper (Chair, BAPEN Medical) & Prof Alastair Forbes (Chair, BSG Small Bowel & Nutrition Committee)

A new International Standard (ISO 80369-3) is being published this year and covers all connectors on enteral devices.

In order to comply with the International Standard, a new global enteral feeding device connector design (named ENFit) will be introduced across the UK from September 2015. The ENFit introduction will be a 2-stage process, with transition giving sets and gravity sets made available from September 2015, followed by ENFit feeding tubes and syringes being introduced from March 2016.

To facilitate the smooth transition to the ISO standard, a group made up of industry, clinical and NHS stakeholders was formed and named the EPSG (Enteral Plastic Safety Group). The EPSG represents all leading UK enteral feeding devices suppliers, with clinical representation from the PENG of the BDA, NNNG and supported by PINNT, BAPEN and BPNG. The following companies are members of the EPSG: Abbott; Corpak; Covidien; Fresenius Kabi; GBUK Enteral (Enteral UK); Intervene; Medicina; Nutricia; Vygon. EPSG member companies and NHS Supply Chain have agreed not to place any ENFit enteral feeding device (other than transition giving sets and gravity sets) into the UK market until 14th March 2016. It is envisaged that this process will minimise disruption to the NHS, whilst maintaining patient safety at all times. For further information about ENFit and how the changeover affects you and your patients, please contact your current enteral devices supplier or any of the following represented clinical groups: PENG of the BDA, NNNG, PINNT, BAPEN, BPNG.

Page 3 of 8